INO vs. CERS, AORT, CATX, SILK, ATRI, KIDS, EMBC, FNA, SRDX, and PLSE
Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Cerus (CERS), Artivion (AORT), Perspective Therapeutics (CATX), Silk Road Medical (SILK), Atrion (ATRI), OrthoPediatrics (KIDS), Embecta (EMBC), Paragon 28 (FNA), Surmodics (SRDX), and Pulse Biosciences (PLSE). These companies are all part of the "surgical & medical instruments" industry.
Inovio Pharmaceuticals (NASDAQ:INO) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.
In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than Cerus. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 4 mentions for Cerus. Cerus' average media sentiment score of 0.86 beat Inovio Pharmaceuticals' score of 0.10 indicating that Cerus is being referred to more favorably in the news media.
26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 2.5% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 3.4% of Cerus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Inovio Pharmaceuticals received 149 more outperform votes than Cerus when rated by MarketBeat users. However, 72.26% of users gave Cerus an outperform vote while only 71.49% of users gave Inovio Pharmaceuticals an outperform vote.
Cerus has higher revenue and earnings than Inovio Pharmaceuticals.
Inovio Pharmaceuticals presently has a consensus target price of $70.67, suggesting a potential upside of 623.30%. Cerus has a consensus target price of $3.83, suggesting a potential upside of 109.47%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Inovio Pharmaceuticals is more favorable than Cerus.
Inovio Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Cerus has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
Cerus has a net margin of -19.27% compared to Inovio Pharmaceuticals' net margin of -16,238.91%. Cerus' return on equity of -58.65% beat Inovio Pharmaceuticals' return on equity.
Summary
Cerus beats Inovio Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Inovio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inovio Pharmaceuticals Competitors List
Related Companies and Tools
